PDF   Print   View All
June 10, 2002
Hemispherx Biopharma Receives New Patent In Europe For Oral Dosed Broad-Spectrum Immune Activators
Philadelphia, PA, Monday, June 10, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today the receipt of a major new patent on a set of orally active low molecular weight RNA compounds, trade marked "ORAGENS," which are designed to function within a broad spectrum of antiviral and immunologic activities.

Because of the unusual breath and scope of the application, nearly 13 years were required for successful prosecution and issuance of the patent. During the intervening years, major collaborations were created with U.S. and European Universities, as well as the National Institute of Health (NIH). The results of these collaborations, published and/or pending publications in major peer review journals, establish the therapeutic promise of these new experimental drug entities in various chronic diseases associated with immune dysfunction and chronic viral replication or viral "footprints."

The intent of the patent is to offer a relative ease and convenience of oral dosaging in chronic diseases where currently injection or infusion is the common method of drug introduction. Typically, oral applications dramatically broaden the use of drugs and increase patient compliance in both clinical trial and post approval use as compared with intravenous infusion or intramuscular injection.

The issued patent, designated "Therapeutic Uses of 2', 5' - oligoadenylate derivatives" is currently being issued in Denmark and covers some 20 or more novel compounds which can be administered orally.

Recently, Hemispherx's European subsidiary, Hemispherx Biopharma Europe S.A. announced a major licensing and equity placement surrounding one of its lead high molecular weight RNA compounds, termed Ampligen®, which is in Phase III clinical trials and is a parentally injected product. Hemispherx is evaluating manufacturing worldwide to facilitate the potential scaling up of production of specific Oragens.

Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc., Philadelphia, PA, is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, please visit the Company's website at http://www.hemispherx.net.

William A. Carter, M.D., CEO & Chairman, Hemispherx Biopharma, Inc.
(215) 988-0080
Dianne Will, Investor Relations, (518) 398-6222, Fax: (518) 398-6223
Robert Giordano, Institutional Investors, MRB, (212) 230-1727, Fax: (212) 230-1734
HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should all be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx Biopharma, Inc. involve risks of competition, changing market conditions, change in laws and regulations effecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.